Pharmahungary Group won an SME Instrument Phase I grant with an innovative in-house R&D project, Vezics, www.vezics.com. Vezics is a highly efficient, scalable chromatography platform for high-quality exosome isolation developed in collaboration with Semmelweis University, Budapest, Hungary in the scope of the National Heart Program of Hungary. For the press release, please follow this link.

With winning the highly competitive SME Instrument grant Pharmahungary Group will further develop Vezics into market-ready high-quality exosome isolation platform. For more information on Vezics please visit www.vezics.com or contact us directly for partnership opportunities at businessdevelopment@pharmahungary.com.